Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4180663 | 0.96 | F10 (0.65) | F10 | |
| SCHEMBL8257147 | 0.85 | F10 (0.64) | F10 | |
| SCHEMBL4177819 | 0.85 | F10 (0.64) | F10 | |
| SCHEMBL4171940 | 0.84 | F10 (0.53) | F10 | |
| SCHEMBL4171444 | 0.83 | F10 (0.54) | F10 | |
| SCHEMBL4176222 | 0.83 | F10 (0.63) | F10 | |
| SCHEMBL4172923 | 0.83 | F10 (0.63) | F10 | |
| SCHEMBL4161614 | 0.83 | F10 (0.63) | F10 | |
| SCHEMBL4171847 | 0.82 | F10 (0.68) | F10 | |
| SCHEMBL8243756 | 0.81 | NR1H2 (0.41) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306045-A1 | 1-Benzazepine-3-Sulfonylamino-2-Pyrroridones as Factor Xa Inhibitors | CAMUS LAURE | 2008-12-11 | — | — | US | disclosed |
| US-20080306045-A1 | 1-Benzazepine-3-Sulfonylamino-2-Pyrroridones as Factor Xa Inhibitors | CAMUS LAURE | 2008-12-11 | — | — | US | disclosed |
| US-20080306045-A1 | 1-Benzazepine-3-Sulfonylamino-2-Pyrroridones as Factor Xa Inhibitors | CAMUS LAURE | 2008-12-11 | — | — | US | disclosed |
| WO-2007059952-A2 | 1-BENZAZEPINE-3-SULFONYLAMINO-2-PYRRLORIDONES AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306045-A1 | 1-Benzazepine-3-Sulfonylamino-2-Pyrroridones as Factor Xa Inhibitors | TFPI, TPSAB1, TFPI2 | F10 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.